Literature DB >> 27736048

Clozapine Use in First-Episode Psychosis: The Singapore Early Psychosis Intervention Programme (EPIP) Perspective.

Charmaine Tang1,2, Mythily Subramaniam3, Boon Tat Ng4, Edimansyah Abdin3, Lye Yin Poon2, Swapna K Verma2.   

Abstract

OBJECTIVE: Early symptomatic response is pertinent in improving outcomes in first-episode psychosis. One of the ways in which this may be achieved is by reducing inappropriate delays in clozapine initiation. This study aimed to examine clozapine prescribing practices among clinicians by establishing the prevalence of clozapine use, identifying baseline clinical and demographic factors that were associated with clozapine use, examining outcomes in clozapine users versus nonusers, and identifying inappropriate antipsychotic prescription patterns prior to clozapine initiation.
METHODS: A retrospective study including all consecutive patients who had presented to the Singapore Early Psychosis Intervention Programme (EPIP) from April 2001 to June 2012 was conducted. Clinical and demographic data were extracted from the EPIP database. Incident cases of clozapine users were identified, and additional treatment histories were obtained from medical records. In addition to descriptive statistics, multivariate analysis was performed to identify factors associated with clozapine initiation.
RESULTS: Data from 1,603 patients were available for baseline analyses. Of these, 69 patients (4.3%) had been prescribed clozapine. Having a younger age at onset, lack of employment, a lower Global Assessment of Functioning disability score, and a higher Positive and Negative Syndrome Scale total score at baseline were factors associated with clozapine use. After adjustment was made for confounders, clozapine users were found to have attained similar rates of remission and recovery as patients who did not use clozapine. Clozapine initiation was delayed by a mean of 19.3 weeks (SD = 27.1; range, 0-117). Prior to commencing clozapine, 29.4% of patients had received antipsychotic treatments above maximum limits, whereas 75% of patients were prescribed ≥ 3 different antipsychotics (median = 3; range, 2-7).
CONCLUSIONS: This study has confirmed that the prescribing of clozapine is low, delayed, and preceded by dosing of antipsychotic drugs above maximum limits. Identification of the factors found to be associated with clozapine use may encourage clinicians to consider clozapine sooner in relevant patients in hopes of achieving early symptomatic response. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27736048     DOI: 10.4088/JCP.15m10063

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

Review 1.  Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern.

Authors:  Alexander Panickacheril John; Elvin Kay Fon Ko; Arun Dominic
Journal:  Can J Psychiatry       Date:  2018-04-22       Impact factor: 4.356

2.  Integrating Genomics into Psychiatric Practice: Ethical and Legal Challenges for Clinicians.

Authors:  Eric T Ward; Kristin M Kostick; Gabriel Lázaro-Muñoz
Journal:  Harv Rev Psychiatry       Date:  2019 Jan/Feb       Impact factor: 3.732

3.  Clozapine Use in Patients with Early-Stage Schizophrenia in a Chinese Psychiatric Hospital.

Authors:  Wenying Yi; Shenglin She; Jie Zhang; Haibo Wu; Yingjun Zheng; Yuping Ning
Journal:  Neuropsychiatr Dis Treat       Date:  2020-11-24       Impact factor: 2.570

4.  One-Year Outcome and Adherence to Pharmacological Guidelines in First-Episode Schizophrenia: Results From a Consecutive Cohort Study.

Authors:  Petros Drosos; Kolbjørn Brønnick; Inge Joa; Jan Olav Johannessen; Erik Johnsen; Rune Andreas Kroken; Helen Joy Stain; Wenche Ten Velden Hegelstad; Tor Ketil Larsen
Journal:  J Clin Psychopharmacol       Date:  2020 Nov/Dec       Impact factor: 3.118

5.  Drug-naïve first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China.

Authors:  Mengran Zhu; Maria Ferrara; Wenjian Tan; Xingbo Shang; Sumaiyah Syed; Li Zhang; Qilin Qin; Xinran Hu; Robert Rohrbaugh; Vinod H Srihari; Zhening Liu
Journal:  Early Interv Psychiatry       Date:  2020-09-14       Impact factor: 2.732

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.